Characterization of epidermal growth factor receptor (EGFR) P848L, an unusual EGFR variant present in lung cancer patients, in a murine Ba/F3 model

Characterization of epidermal growth factor receptor (EGFR) P848L, an unusual EGFR variant present in lung cancer patients, in a murine Ba/F3 model

Lung cancer patients with mutations in epidermal growth factor receptor (EGFR) benefit from treatments targeting tyrosine kinase inhibitors (TKIs). However, both intrinsic and acquired resistance of tumors to TKIs are common, and EGFR variants have been identified that are resistant to multiple TKIs...

Full description

Bibliographic Details
Main Authors: Bhaswati Sarcar, Nicholas T. Gimbrone, Gabriela Wright, Lily L. Remsing Rix, Edna R. Gordian, Uwe Rix, Alberto A. Chiappori, Gary W. Reuther, Pedro G. Santiago‐Cardona, Teresita Muñoz‐Antonia, William Douglas Cress
Format: Article
Language:English
Published: Wiley 2019-10-01
Series:FEBS Open Bio
Subjects:
Ba/F3 cells
EGFR mutation
Janus kinase inhibitor
lung cancer
Tyr 1045
tyrosine kinase inhibitor
Online Access:https://doi.org/10.1002/2211-5463.12702

Internet

https://doi.org/10.1002/2211-5463.12702

Similar Items